Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer

Experimental Biology and Medicine

Volumn 238, Issue 6, 2013, Pages 589-599

  Zagon, Ian S ^a   Porterfield, Nancy K ^a   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Met5 enkephalin; cyclin dependent inhibitory kinase pathways; DNA synthesis; Opioid growth factor; opioid growth factor receptor; triple negative breast cancer

Indexed keywords

GROWTH FACTOR; GROWTH FACTOR RECEPTOR; NEUTRALIZING ANTIBODY; OPIOID GROWTH FACTOR; OPIOID GROWTH FACTOR RECEPTOR; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; FEMALE; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING;

[MET5]-ENKEPHALIN; CYCLIN-DEPENDENT INHIBITORY KINASE PATHWAYS; DNA SYNTHESIS; OPIOID GROWTH FACTOR; OPIOID GROWTH FACTOR RECEPTOR; TRIPLE-NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; NALTREXONE; OPIOID PEPTIDES; RECEPTORS, OPIOID;

EID: 84881605236     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213489492     Document Type: Article

References (27)

1. Jemal A,Bray F,Center MM,Ferlay J,Ward E,Forman D.Global cancer statistics.CA Cancer J Clin. 2011;61:69-90.
2. Siegel R,DeSantis C,Virgo K,Stein K,Mariotto A,Smith T,Cooper D,Gansler T,Lerro C,Fedewa S,Lin Ch,Leach C,Cannady RS,Cho H,Scoppa S,Hachey M,Kirch R,Jemal A,Ward F.Cancer treatment and survivorship statistics 2010.CA Cancer J Clin. 2012;62:220-41.
3. Zagon IS,Donahue RN,McLaughlin PJ.Opioid growth factor - opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.Am J Physiol Regul Integr Comp Physiol. 2009;297:R1154-61.
4. Donahue RN,McLaughlin PJ,Zagon IS.Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.Am J Physiol Regul Integr Comp Physiol. 2009;296:R1716-25.
5. Donahue RN,McLaughlin PJ,Zagon IS.The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.Gynecol Oncol. 2011;122:382-8.
6. McLaughlin PJ,Stack BC,Levin RJ,Fedok F,Zagon IS.Defects in the OGF receptor (OGFr) in human squamous cell carcinoma of the head and neck.Cancer. 2003;97:1701-10.
7. McLaughlin PJ,Kreiner S,Morgan CR,Zagon IS.Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor (OGFr).Int J Oncol. 2008;4:751-7.
8. Zagon IS,Jaglowski JR,Verderame MF,Leure-duPree AE,Smith JP,McLaughlin PJ.Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.Cancer Chemother Pharmacol. 2005;56:510-20.
9. Avella DM,Kimchi ET,Donahue RN,Tagaram HR,McLaughlin PJ,Zagon IS,Staveley-O'Carroll KF.The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.Am J Physiol Regul Integr Comp Physiol. 2010;298:R459-66.
10. Fogh J.Absence of HeLa cell contamination in 169 cell lines derived from human tumors.J Natl Cancer Inst. 1977;58:209-14.
11. Lasfargues EY,Ozzello L.Cultivation of human breast carcinomas.J Natl Cancer Inst. 1958;21:1131-47.
12. Brandes LJ,Hermonat MW.Receptor status and subsequent sensitivity of subclones of MCF-7 human breast cancer cells surviving exposure to diethylstilbestrol.Cancer Res. 1983;43:2831-5.
13. Trempe GL.Human breast cancer in culture.Recent results Cancer Res. 1976;57:33-41.
14. Zagon IS,McLaughlin PJ.Production and characterization of polyclonal and monoclonal antibodies to the zeta opioid receptor.Brain Res. 1993;630:295-302.
15. Zagon IS,Verderame MF,McLaughlin PJ.The biology of the opioid growth factor receptor (OGFr).Brain Res Rev. 2002;38:351-76.
16. McLaughlin PJ,Verderame MF,Hankins JL,Zagon IS.Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck.Int J Mol Med. 2007;19:421-8.
17. Cheng F,Zagon IS,Verderame MF,McLaughlin PJ.The OGF-OGFr utilizes the p16 pathway to restrict progression of human squamous cell carcinoma of the head and neck.Cancer Res. 2007;67:10511-8.
18. Cheng F,McLaughlin PJ,Verderame MF,Zagon IS.The OGF-OGFr utilizes the p21 pathway to restrict progression of human pancreatic cancer.Mol Cancer. 2007;7:5-17.
19. Jaglowski JR,Zagon IS,Stack BC,Verderame MF,Leure-duPree AE,Manning JD,McLaughlin PJ.Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck.Cancer Chemother Pharmacol. 2005;56:97-104.
20. Donahue RN,Zagon IS,McLaughlin PJ.The opioid growth factor inhibits established ovarian cancer in nude mice and can be combined with taxol or cisplatin to enhance growth inhibition.J Cancer Ther. 2011;2:110-24.
21. Vogel VG.Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.Curr Drug Targets. 2011;12:1874-87.
22. Leeper AD,Farrell J,Williams LJ,Thomas JS,Dixon JM,Wedden SE,Harrison DJ,Katz E.Determining tamoxifen sensitivity using primary breast cancer tissue in collage-based three-dimensional culture.Biomaterials. 2012;33:907-15.
23. Tate CR,Rhodes LV,Segar HC,Driver JL,Pounder FN,Burow ME,Collins-Burow BM.Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.Breast Cancer Res. 2012;14:R79-R79.
24. Rahman M,Davis SR,Pumphrey JG,Bao J,Nau MM,Meltzer PS,Lipkowitz S.TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype.Breast Cancer Res Treat. 2009;113:217-30.
25. Miller WR,Dixon JM,Macfarlane L,Cameron D,Anderson TJ.Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen.Eur J Cancer. 2003;39:462-8.
26. Mueller KL,Madden JM,Zoratti GL,Kuperwasser C,List K,Boerner JL.Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.Breast Cancer Res. 2012;14:R104-R104.
27. Lehmann BD,Bauer JA,Chen X,Sanders ME,Chakravarthy AB,Shyr Y,Pietenpol JA.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.J Clin Invest. 2011;121:2750-67.